Only 15.8% of the population in low-income countries is double-dosed. Vaccine hoarding by high income countries is to blame.
Academic rigor, journalistic flair
Articles on Vaccine distribution
Displaying 1 - 20 of 27 articles
An inhaled COVID-19 vaccine would go directly to where the body would use it: the mucosal surface of the airways. This could mean less waste and more benefit, lower costs and reduced side-effects.
We’re reliant on overseas supply - and the many moving parts of delivery. Each of those parts require staff on the ground – and many workers in this system are likely being affected by Omicron.
COVAX, the global vaccine distribution initiative, is well behind its goal of delivering 2 billion doses this year due to under-investment, vaccine nationalism and export restrictions.
We’ll need mass vaccination hubs and expanded GP vaccination clinics to deliver jabs to millions of Australians.
From today, around 1,000 clinics around the country can begin vaccinating eligible Australians.
Italy’s decision to block export of AstraZeneca vaccines to Australia will likely not impact our vaccine roll-out. But vaccine scarcity is a looming problem in other parts of the world.
Fair global agreements, home-grown vaccines and sharing extra doses with poorer nations are all needed if we’re to ever emerge from this pandemic.
The global vaccine rollout has not been free from geopolitical rivalries and point-scoring.
The clock starts ticking once the vaccine leaves the freezer. Here’s what to expect.
The Oxford/AstraZeneca vaccine is the second COVID shot to be approved in Australia, and it’s likely Australians will start receiving it next month.
People with disabilities are overlooked for COVID-19 vaccine distribution and triage protocols. We need to make this group a priority and address issues that put them at risk.
Vaccine hesitancy will not go away fast. In fact, there are parallels in the physical world to how quickly or slowly an object returns to its normal state.
From designing vaccine supply chains to improving PPE to rebuilding trust, systematically bringing engineering knowhow to public health problems could make a huge difference.
Rollout of COVID-19 vaccines has begun. But getting the jab doesn’t mean abandoning masks, distancing and handwashing. Here’s why the current preventive measures must continue post-vaccine.
West Virginia’s success holds some important lessons for other states and the rest of the COVID-19 vaccine rollout.
With reports emerging of vaccine wastage across the world, medical supply chain experts explain why that’s to be expected.
With vaccine shortages looming, experts are debating whether it is important to receive two doses or whether it’s better to give one dose to more people and give a second when the supply is better.
The shipment of goods to suppliers has become technologically sophisticated. Delays in getting out the COVID-19 vaccine to people show that the breakdowns come down to something more basic.
So far, the only COVID-19 vaccines authorized for use need to be kept frozen. But there are many places in the world that can’t support a cold supply chain.
Top contributors
-
Associate Professor in Public Health, La Trobe University
-
Director of the Digital Health Enterprise Zone (DHEZ), University of Bradford, Professor of Health Service Operations, University of Bradford
-
Assistant Professor Supply Chain Management & Social Responsibility, Hanken School of Economics
-
Professor of Operations Management & Business Analytics, Carey Business School, Johns Hopkins University
-
Associate Principal Research Fellow, Burnet Institute
-
Professor of Global Biosecurity, NHMRC Principal Research Fellow, Head, Biosecurity Program, Kirby Institute, UNSW Sydney
-
Professor in Global Development, SOAS, University of London
-
Senior Technical Advisor - HIV, The Nossal Institute for Global Health, PhD candidate La Trobe University, The University of Melbourne
-
Associate professor, University of Sydney
-
Professor and Eugene M. Isenberg Chair in Integrative Studies, UMass Amherst
-
Associate Professor, Discipline of Childhood and Adolescent Health, University of Sydney
-
Associate Professor in Commercial Law, Te Herenga Waka — Victoria University of Wellington
-
Research Fellow, UNSW Sydney
-
Professor of Pharmaceutics, The University of Texas at Austin
-
Research associate, Warren Alpert Medical School, Brown University, Brown University
